About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT04315753

Circulating and Imaging Biomarkers to Improve Lung Cancer Management and Early Detection

Validation of biomolecular markers in the circulation and radiomic features are the focus of this project.The aim is to assess the role of molecular and cellular biomarkers (exosomes antigens, Circula...

Lead sponsor: Istituto Clinico Humanitas•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Giulia Veronesi, MD

CONTACT

02 26435278 veronesi.giulia@hsr.it

Sponsors

Lead Sponsor

Istituto Clinico Humanitas

Collaborators

Ospedale San Raffaele
University of Paris 5 - Rene Descartes
European Institute of Oncology
Istituto Superiore di Sanità

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age ≥ 55 years old and exposure to smoking more than 30 packs-year; which corresponds to 6-year risk of lung cancer, calculated according to the plco score (≥ 2%).
•Smoker or former smoker Former smokers must have ceased smoking within the 15 years prior to enrollment in the study.
•Absence of symptoms of lung cancer such as worsening of cough, hoarseness, hemoptysis and weight loss.

Exclusion Criteria

•Previous diagnosis of lung cancer.
•Positive extrapulmonary cancer history in the last 5 years (excluding in situ tumors or skin epidermoid tumor).
•Performing a chest CT scan in the last 18 months.
•Severe lung or extrapulmonary diseases that may preclude or invalidate appropriate therapy in case of diagnosis of malignant pulmonary neoplasia.

Related studies

Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates

NCT06689488 · Lung Cancer

Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

NCT00899405 · Lung Cancer

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more

RECRUITINGPhase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 20, 2020Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment2,000

Start dateJan 2018

Last updatedMar 20, 2020

Condition

Locations shown

Istituto Clinico Humanitas

Rozzano, Milano

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions